Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2811-y ◽

2015 ◽

Vol 76 (2) ◽

pp. 397-408 ◽

Author(s):

Clarinda Chua ◽

Iain Beehuat Tan ◽

Yasuhide Yamada ◽

Sun Young Rha ◽

Wei Peng Yong ◽

...

Keyword(s):

Gastric Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Her2 Positive ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3535 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3535-3535 ◽

Author(s):

E. Díaz Rubio ◽

J. Tabernero ◽

E. van Cutsem ◽

A. Cervantes ◽

T. André ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80997-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 199

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1053 ◽

2008 ◽

Vol 14 (1) ◽

pp. 215-223 ◽

Author(s):

G. Folprecht ◽

J. Tabernero ◽

C.-H. Kohne ◽

C. Zacharchuk ◽

L. Paz-Ares ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Receptor Tyrosine Kinase ◽

Growth Factor Receptor ◽

Line Treatment ◽

Irreversible Inhibitor ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(11)72435-2 ◽

2011 ◽

Vol 47 ◽

pp. S630

Author(s):

K. Asami ◽

T. Koizumi ◽

K. Hirai ◽

S. Ameshima ◽

A. Tsukadaira ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

Small Cell Lung ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Journal of Clinical Oncology ◽

10.1200/jco.2016.70.2472 ◽

2017 ◽

Vol 35 (6) ◽

pp. 692-692 ◽

Author(s):

Young Hak Kim

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Small Cell Lung ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.145851 ◽

2014 ◽

Vol 10 (7) ◽

pp. 155 ◽

Author(s):

Fang Li ◽

Nan Du ◽

Xiao Zhao ◽

Guangqin Zhu ◽

Huoming Chen ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Brain Metastasis ◽

Lung Adenocarcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

Lung Cancer ◽

10.1016/j.lungcan.2010.12.008 ◽

2011 ◽

Vol 71 (3) ◽

pp. 249-257 ◽

Author(s):

C. Gridelli ◽

F. De Marinis ◽

M. Di Maio ◽

D. Cortinovis ◽

F. Cappuzzo ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Small Cell Lung ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Oncology ◽

10.1159/000453336 ◽

2017 ◽

Vol 92 (4) ◽

pp. 205-212 ◽

Author(s):

Hiroko Hasegawa ◽

Hiroya Taniguchi ◽

Seiichiro Mitani ◽

Toshiki Masuishi ◽

Azusa Komori ◽

...

Keyword(s):

Colorectal Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Second Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text